NCT03097068View on ClinicalTrials.gov

Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis

PHASE4CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

April 19, 2017

Primary Completion Date

December 6, 2017

Study Completion Date

February 2, 2018

Conditions

Diabetic Macular Edema

Interventions

DRUG

Lucentis

0.3mg Lucentis

Trial Locations (1)

49546

Vitreo-Retinal Associates, Grand Rapids

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Michigan State University

OTHER

lead

Vitreo-Retinal Associates, Michigan

OTHER